DESIGN THERAPEUTICS INC (DSGN) Stock News
NASDAQ:DSGN - Nasdaq - US25056L1035 - Common Stock - Currency: USD
DSGN Latest News and Analysis
Monday's pre-market session: top gainers and losers
Discover the top movers in Monday's pre-market session and stay informed about market dynamics.
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing...
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to...
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio
Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with...
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them.
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024
DSGN stock results show that Design Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Design Therapeutics (NASDAQ:DSGN) just reported results for the first quarter o...
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal...
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious...
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023
DSGN stock results show that Design Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Design Therapeutics (NASDAQ:DSGN) just reported results for the fourth quarter ...
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by...
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious...
Biogen gets EU approval for Friedrich's ataxia drug (NASDAQ:BIIB)
Biogen (BIIB) said it has received EU approval for its drug Skyclarys for the treatment of Friedreich’s ataxia, or FA, in patients aged 16 years and older. Read more here.